Dose Tapering

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis

This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d